

---

## **INTRODUCING A NEW GLOBAL ALLERGY COMPANY**

**DATE: 6 November 2015**

London (United Kingdom) - Stallergenes Greer plc (Euronext: STAGR) held on 5 November 2015 a webcast business update, hosted by Chairman and CEO, Fereydoun Firouz. This update covered the company's corporate strategy and short to mid-term priorities following the combination of Stallergenes and Greer Laboratories.

Fereydoun Firouz shared the significant and rapid progress being made in integrating Stallergenes and Greer to create a fully integrated, global biopharmaceutical company. Stallergenes Greer is now the only Allergy Immunotherapy (AIT) company with a complete subcutaneous, sublingual liquid and tablet portfolio, and the financial means to accelerate its current growth trajectory. Stallergenes Greer plc had combined sales in 2014 of €312.5 million (USD 344 million), EBITDA of €89.2 million (USD 98.3 million) and over 1,400 employees worldwide. The Company's business model, which is focused on select strategic research programs, manufacturing, development, marketing and M&A, will allow the Company to grow globally, in the expanding allergy immunotherapy market.

Fereydoun Firouz said: *"Our purpose is to enable people with allergies to live normal lives. We are excited about our portfolio of AIT products in both EU and US markets and we are investing to strengthen our existing global leadership position with enhanced focus on the US market. We have made significant progress in integrating the companies in the context of defining our strategy, our brand, shaping the organization, governance model and focusing on where the true value is for all our stakeholders. Given our purpose, we will continue to invest in delivering life changing medicines and expand our geographical footprint in a targeted manner."*

**For more information, please visit our webcast on our new website [www.stallergenesgreer.com](http://www.stallergenesgreer.com)**

### **FINANCIAL CALENDAR**

- |                                       |                |
|---------------------------------------|----------------|
| • Full Year 2015 revenues and results | 9 March 2016   |
| • R&D day                             | Q2 2016        |
| • H1 2016 revenues and results        | 25 August 2016 |
| • Investor day                        | Q4 2016        |

---

**ABOUT STALLERGENES GREER PLC**

Headquartered in London (UK), Stallergenes Greer plc is a global company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

**Trading information:**

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification: 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>

**Contacts:**

**Investor and analyst relations**

Peter Bühler

Chief Financial Officer

Tel: +33 1 55 59 23 22

Email: [investorrelations@aresallergyco.com](mailto:investorrelations@aresallergyco.com)

**Media relations**

Lise Lemonnier

Head of Global Communications

Tel: + 33 1 55 59 20 96

Email: [llemonnier@stallergenes.com](mailto:llemonnier@stallergenes.com)

**Investor and Media relations agency:**

Robin Wrench / Agnes Catineau

Brunswick Group

Email: [stallergenesgreer@brunswickgroup.com](mailto:stallergenesgreer@brunswickgroup.com)

Tel: +44 (0)20 7404 5959

+33 (0) 6 19 17 16 67